Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405
- Citation:
- J Clin Oncol vol 34 (suppl) abstr 3597
- Meeting Instance:
- ASCO 2016
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3616
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- GI
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Andrew B. Nixon Alexander B. Sibley Ace J. Hatch Yingmiao Liu Chen Jiang Flora Mulkey Mark D. Starr John C. Brady Donna Niedzwiecki Federico Innocenti Alan P. Venook Howard Hochster Heinz-Josef Lenz Kouros Owzar Herbert I. Hurwitz
- Networks:
- CA011, CA136, LAPS-MA036, LAPS-NC007, LAPS-NC010
- Study
- CALGB-80405
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: